Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-15
    E.g., 2018-11-15

Articles

9185 items
11:41 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary Cell culture and rat studies identified a pyrrolidine sulfonamide-based TRPV4 inhibitor that could help treat pulmonary edema associated with heart failure. Chemical synthesis and testing of pyrrolidine sulfonamide analogs in cell-based activity assays, followed...
11:41 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine/Metabolic; neurology

INDICATION: Porphyria; pain Mouse, rabbit and monkey studies suggest a lipid nanoparticle (LNP)-encapsulated mRNA encoding HMBS could help treat acute intermittent porphyria (AIP), which is caused by hepatic HMBS deficiency, and AIP-associated pain. In mouse...
11:40 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Inflammation

INDICATION: Asthma Rat studies suggest antagonizing TRPV1 or combined antagonism of its upstream activators LPAR1, LPAR2, LPAR3 and LPAR4 could help treat allergic asthma. In a rat model of allergic asthma, plasma levels of lysophosphatidic acid...
11:39 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Rat and mouse studies suggest inhibiting the long non-coding RNA (lncRNA) NEAT1 could help treat neointimal hyperplasia. In carotid artery samples from a rat model of angioplasty-associated neointimal hyperplasia, NEAT1 levels were higher...
11:39 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample and mouse studies suggest T cell-specific inhibition of XBP1 or IRE1 could help treat ovarian cancer. In tumor and ascites samples from patients, high T cell expression of XBP1 was...
11:39 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Seizures In silico, cell culture and mouse studies identified a GABRB2/GABRB3 positive allosteric modulator (PAM) that could help treat seizures. In silico screening of a small molecule library for structural similarity to a pharmacophore model...
11:38 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Porphyria In vitro, cell culture and mouse studies suggest ciclopirox could help treat congenital erythropoietic porphyria (CEP), which is caused by destabilizing mutations in UROS. Fragment-based screening, structural comparison of the top screening hits with...
11:38 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Rat studies suggest human embryonic stem cell (hESC)-derived spinal cord neural stem cells (NSCs) could help treat SCI. hESCs were cultured with fibroblast growth factors and inhibitors of bone morphogenic protein,...
11:38 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL) Mouse studies suggest hematopoietic stem cells (HSCs) expressing IFNα could help treat B cell ALL (B-ALL). In a mouse model of B-ALL, HSCs modified to express IFNα decreased leukemic cell growth...
4:00 PM, Oct 11, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified an inhibitor of the transmembrane domain of p75 NTR that could help treat melanoma. Screening of a compound library in a binding assay in bacteria expressing the...

Pages